考格列汀片 | China Drugs ListCofrogliptin Tablets | China Drugs List
本页为公开参考信息，不构成医疗建议、处方或药品供应要约。请向持证专业人士确认当前批准情况、可获得性及适用性。
- 企业
- 海思科医药集团股份有限公司Haisco Pharmaceutical Group Co., Ltd.
- 药品类型
- 化学药Chemical medicine
- 治疗领域
- 内分泌与代谢Endocrinology & metabolism
- 公开来源记录的适应症
- 配合饮食控制和运动，改善成人2型糖尿病患者的血糖控制：①单药治疗；②在单独使用盐酸二甲双胍血糖控制不佳时，与盐酸二甲双胍联合使用。To improve glycemic control in adults with type 2 diabetes: (1) as monotherapy alongside diet and exercise; (2) in combination with metformin hydrochloride alongside diet and exercise when metformin hydrochloride alone does not provide adequate glycemic control.
- 适应症来源与口径
- 来源日期： 2026-06. 批准或修订日期为空或为占位值；尚未确认准确修订日期。Source date(s): 2026-06. An approval or revision date is blank or a placeholder; the exact revision date is not confirmed.
- 说明书信息局限
- 已取得完整官方药品说明书。 中国大陆说明书。Complete official prescribing information obtained. Mainland China label.
- 中国可获得性状态
- 已核实中国历史批准记录；尚未逐项核查每个产品目前是否持续上市销售。Historical Chinese approval verified; current continuous market availability has not been checked for every product.
- 海外状态
- 待逐一核查各市场。Market-by-market verification pending.
- 医保分类
- 已纳入国家医保（乙类）Included in national insurance (Category B)
- 医保版本
- 2025版；2026年1月1日起执行2025 edition; effective 1 January 2026
- 医保限制
- 该目录条目未另列限定；仍须遵守目录凡例及法定适应症No additional restriction is specified for this list entry; the list's general rules and approved indications still apply.
- 医保期限
- 2025-01-01 至 2026-12-312025-01-01 to 2026-12-31
- 医保核查说明
- 按成分／剂型名称精确或标准化匹配。报销仍取决于剂型及目录所列支付限制。Matched by exact or normalized ingredient/formulation name. Reimbursement still depends on the dosage form and listed payment restrictions.